Israel vaccinates hard and is in the lead. More than 4.3 million of its inhabitants – 48% of the population – have received at least one dose of the Pfizer-BioNTech vaccine. And 2.9 million (32%) have even benefited from the second, since the campaign began on December 19. The Hebrew state received XXL quantities of the American-German serum in exchange for patient data on its effectiveness. Enough to produce robust statistics today.
Unveiled by the Ynet information site and spotted by Reuterson Thursday evening, a study by the Israeli Ministry of Health and Pfizer showed that this RNA vaccine reduced the risk of infection by 89.4% in asymptomatic cases and 93.7% in symptomatic cases after the second dose, injected at least seven days before. Percentages based on data as of February 6. The vaccine was also found to be effective against the British variant of the coronavirus, which accounts for around 80% of confirmed cases in Israel. The findings of this study have not yet been published by a peer-reviewed scientific journal.
98.9% efficiency in severe forms
The Israeli Minister of Health came to drive the point home on Saturday, bringing even more recent figures, arrested on February 13: he announced that the risk of infection from covid-19 fell by 95.8% in people who received both doses Pfizer’s vaccine, the second of which was at least two weeks earlier. Better still, the vaccine was also 98% effective in preventing fever or respiratory problems and 98.9% in preventing hospitalizations and deaths, the ministry said.
Another very encouraging study: that carried out by the Israeli hospital Sheba. Posted Friday in The Lancet magazine, she estimates the reduction in the infection rate of symptomatic cases of covid-19 at 85%, two to four weeks after the first injection. And even at 75% the reduction in the risk of being positive, in the group of asymptomatic patients detected by tests. Excellent figures which revive the debate on the need or not for the second dose …
In addition, the reduction in the risk of infection seen in people without symptoms is an indication of the effectiveness of the vaccine in stopping transmission. Asymptomatic or presymptomatic are indeed responsible for half of the contaminations, according to a study from Jama.
In arriving at these conclusions, the hospital based its work on 9,109 staff, of whom 7,214 received the first dose, not the rest. As of January 24, 170 people across the board have tested positive, of which 89 were in the group of workers who did not receive the first injection. Note that only employees showing symptoms or having been in contact with people who contracted the virus were tested as part of this study. The number of asymptomatic cases could therefore be minimized. Another downside, the sample of people over 65 is very small since it is only constructed with hospital staff.
Support a professional editorial staff at the service of Brittany and the Bretons: subscribe from € 1 per month.